Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol.

BRAF anaplastic neoadjuvant thyroid cancer

Journal

Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430

Informations de publication

Date de publication:
15 Aug 2024
Historique:
revised: 18 06 2024
received: 06 03 2024
accepted: 26 07 2024
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 15 8 2024
Statut: aheadofprint

Résumé

Anaplastic thyroid cancer (ATC), a rare and highly aggressive malignancy, is characterized by an exceptionally poor prognosis, where the majority of patients present with extensive local invasion and/or distant metastases. 20-30% of ATCs harbor the BRAF-V600E mutation. Neoadjuvant BRAF-targeted therapy may have the potential to downstage and facilitate surgical resection for patients with locally advanced and unresectable primary tumors with BRAF mutation and may convey a survival advantage in those with metastatic disease. There is emerging evidence to support the use of other targeted agents, including multikinase inhibitors, as well as the incorporation of immunotherapy into the treatment regimen. Rapid molecular and pathological diagnosis and expert multidisciplinary discussion at specialized treatment centers are critical to expedite investigations and initiate treatment for this complex and rapidly progressive disease.

Identifiants

DOI: 10.1111/ajco.14106 PMID: 39145924
pubmed: 39145924
doi: 10.1111/ajco.14106
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 The Author(s). Asia‐Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd.

Références

Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh IY, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res. 2019;11(9):5888‐5896.
Filetti S, Durante C, Hartl D, et al. Thyroid cancer: eSMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2019;30(12):1856‐1883.
Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86(12):1848‐1853.
McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50‐year experience at a single institution. Surgery. 2001;130(6):1028‐1034.
Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000–2019. JAMA Oncol. 2020;6(9):1397‐1404.
Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021;31(3):337‐386.
Thyroid Cancer Version 4. 2023. National Comprehensive Cancer Network, Inc. 2023.
Davis MP, Bruera E, Morganstern D. Early integration of palliative and supportive care in the cancer continuum: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2013:144‐150.
Silver Karcioglu A, Iwata AJ, Pusztaszeri M, Abdelhamid Ahmed AH, Randolph GW. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): update on the 2021 ATA ATC guidelines. Cancer Cytopathol. 2022;130(3):174‐180.
Chen TY, Lorch JH, Wong KS, Barletta JA. Histological features of BRAF V600E‐mutant anaplastic thyroid carcinoma. Histopathology. 2020;77(2):314‐320.
Xu B, David J, Dogan S, et al. Primary high‐grade non‐anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology. 2022;80(2):322‐337.
Bullock M, O'Neill C, Chou A, et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012;19(6):779‐784.
Wong KS, Lorch JH, Alexander EK, et al. Clinicopathologic features of mismatch repair‐deficient anaplastic thyroid carcinomas. Thyroid. 2019;29(5):666‐673.
Medicare Benefits Schedule—Item 61612: Australian Government Department of Health and Aged Care. 2023. [Available from: https://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=61612Medicare Benefits Schedule—Item 61612
Hu S, Helman SN, Hanly E, Likhterov I. The role of surgery in anaplastic thyroid cancer: a systematic review. Am J Otolaryngol. 2017;38(3):337‐350.
Saeed NA, Kelly JR, Deshpande HA, et al. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head Neck. 2020;42(5):1031‐1044.
Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S. Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival. Head Neck. 2016;38(1):E2083‐2090. Suppl.
Sherman EJ, Harris J, Bible KC, et al. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double‐blind, placebo‐controlled, multicentre, phase 2 trial. Lancet Oncol. 2023;24(2):175‐186.
De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1137‐1143.
Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 1987;60(10):2372‐2375.
Oliinyk D, Augustin T, Koehler VF, et al. Hypofractionated radiotherapy for anaplastic thyroid cancer: systematic review and pooled analysis. Cancers (Basel). 2020;12(9).
Stavas MJ, Shinohara ET, Attia A, Ning MS, Friedman JM, Cmelak AJ. Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma. J Thyroid Res. 2014;2014:764281.
Sherman EJ, Lim SH, Ho AL, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re‐evaluation including uniform pathologic review. Radiother Oncol. 2011;101(3):425‐430.
Silver Karcioglu A, Abdelhamid Ahmed AH, Feng Z, et al. Return of vocal fold motion and surgical preservation of invaded recurrent laryngeal nerves after the use of neoadjuvant therapy in patients presenting with advanced thyroid cancer and vocal fold paralysis: the Lazarus effect. Thyroid. 2023;33(10):1259‐1263.
Wang JR, Zafereo ME, Dadu R, et al. complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)‐mutated anaplastic thyroid carcinoma. Thyroid. 2019;29(8):1036‐1043.
Zhao X, Wang JR, Dadu R, et al. Surgery after BRAF‐directed therapy is associated with improved survival in BRAF(V600E) mutant anaplastic thyroid cancer: a single‐center retrospective cohort study. Thyroid. 2023;33(4):484‐491.
Hu J, Liu K, Ghosh C, Khaket TP, Shih H, Kebebew E. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics. J Exp Clin Cancer Res. 2024;43(1):85.
Filetti S, Durante C, Hartl DM, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33(7):674‐684.
TAFINLAR (Novartis Pharmaceuticals Australia Pty Ltd): Australian Government, Department of Health and Aged Care. 2019. [Available from: https://www.tga.gov.au/resources/prescription‐medicines‐registrations/tafinlar‐novartis‐pharmaceuticals‐australia‐pty‐ltd‐0
Melanoma metastatic daBRAFEnib and tRAMEtinib ID 1619 v4 Sydney: Cancer Institute NSW. 2022. [Available from: https://www.eviq.org.au/medical‐oncology/skin/melanoma‐metastatic/1619‐melanoma‐metastatic‐dabrafenib‐and‐trametinib
Waguespack SG, Drilon A, Lin JJ, et al. Efficacy and safety of larotrectinib in patients with TRK fusion‐positive thyroid carcinoma. Eur J Endocrinol. 2022;186(6):631‐643.
Drilon A, Tan DSW, Lassen UN, et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion‐positive lung cancers. JCO Precis Oncol. 2022;6:e2100418.
Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET‐altered thyroid cancers. N Engl J Med. 2020;383(9):825‐835.
Vitrakvi: Australian Government, Department of Health and Aged Care; 2020 [Available from: https://www.tga.gov.au/resources/auspmd/vitrakvi
Rozlytrek: Australian Government, Department of Health and Aged Care; 2020 [Available from: https://www.tga.gov.au/resources/auspmd/rozlytrek
Retevmo: Australian Government, Department of Health and Aged Care; 2020 [Available from: https://www.tga.gov.au/resources/auspmd/retevmo
Gavreto: Australian Government, Department of Health and Aged Care; 2023 [Available from: https://www.tga.gov.au/resources/auspmd/gavreto
Han PZ, Ye WD, Yu PC, et al. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer. JCI Insight. 2024;9(8).
Brauner E, Gunda V, Vanden Borre P, et al. Combining BRAF inhibitor and anti PD‐L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016;7(13):17194‐17211.
Hamidi S, Iyer PC, Dadu R, et al. Checkpoint inhibition in addition to dabrafenib/trametinib for BRAF(V600E)‐mutated anaplastic thyroid carcinoma. Thyroid. 2024;34(3):336‐346.
Cabanillas ME, Gunn GB, Zafereo ME, et al. IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): phase II trial adjuvant pembrolizumab after IMRT in ATC. J Clin Oncol. 2023;41(16):TPS6117‐TPS. _suppl.
Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base. Cancer. 2017;123(9):1653‐1661.
Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600‐mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7‐13.
COSA guidelines for the safe prescribing, dispensing and administration of systemic cancer therapy Sydney. Clinical Oncology Society of Australia (COSA). 2017. [Available from: https://wiki.cancer.org.au/australia/COSA:Cancer_chemotherapy_medication_safety_guidelines
Patient information—Melanoma metastatic—Dabrafenib and trametinib Sydney. Cancer Institute NSW. 2022. [Available from: https://www.eviq.org.au/medical‐oncology/skin/melanoma‐metastatic/1619‐melanoma‐metastatic‐dabrafenib‐and‐trametinib/patient‐information
Takahashi S, Kiyota N, Yamazaki T, et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019;15(7):717‐726.
Wirth LJ, Brose MS, Sherman EJ, et al. Open‐label, single‐arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol. 2021;39(21):2359‐2366.
Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31(7):1076‐1085.
Dierks C, Ruf J, Seufert J, et al. 1646MO Phase II ATLEP trial: final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Annal Oncol. 2022; 33:S1295.
Iyer PC, Dadu R, Gule‐Monroe M, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6(1):68.
Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E‐mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406‐415.
FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation. US FDA. 2018. [Available from: https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐approves‐dabrafenib‐plus‐trametinib‐anaplastic‐thyroid‐cancer‐braf‐v600e‐mutation
Oh DY, Algazi A, Capdevila J, et al. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study. Cancer. 2023;129(8):1195‐1204.
Kollipara R, Schneider B, Radovich M, Babu S, Kiel PJ. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. Oncologist. 2017;22(10):1149‐1151.
Nabhan F, Kander E, Shen R, et al. Pembrolizumab in a patient with treatment‐naive unresectable BRAF‐mutation negative anaplastic thyroid cancer. Case Rep Endocrinol. 2021;2021:5521649.
Australian Public Assessment Report for Keytruda: Australian Government Department of Health, Therapeutic Goods Administration. 2023. [Available from: https://www.tga.gov.au/sites/default/files/2023‐05/auspar‐keytruda‐230508.pdf
Cabanillas ME, Williams MD, Gunn GB, et al. Facilitating anaplastic thyroid cancer specialized treatment: a model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck. 2017;39(7):1291‐1295.
Koda K, Katoh M, Yasuhara K. Management of anaplastic thyroid cancer and proposed treatment guidelines‐A 5‐year case series study. Cancer Rep (Hoboken). 2022;5(11):e1727.

Auteurs

Anna K Lawless (AK)

Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
ORCID: 0000-0003-3811-2916

Shejil Kumar (S)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Jessica Bindra (J)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Mark Sywak (M)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Endocrine Surgical Unit, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Angela Chou (A)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia.
Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

John Turchini (J)

Anatomical Pathology, Douglass Hanly Moir Pathology, Macquarie Park, New South Wales, Australia.
Discipline of Pathology, Macquarie Medical School, Macquarie University, Sydney, New South Wales, Australia.

Alexander Papachristos (A)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Endocrine Surgical Unit, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Ayanthi Wijewardene (A)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Cancer Genetics, Kolling Institute of Medical Research, Sydney, Australia.

Stanley Sidhu (S)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Endocrine Surgical Unit, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Mahsa Ahadi (M)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia.
Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Lyndal Tacon (L)

Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Cancer Genetics, Kolling Institute of Medical Research, Sydney, Australia.

Anthony Glover (A)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Endocrine Surgical Unit, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Katherine Clark (K)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of Palliative Care, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Venessa Tsang (V)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Leo Pang (L)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of ENT Surgery, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Roderick J Clifton-Bligh (RJ)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Cancer Genetics, Kolling Institute of Medical Research, Sydney, Australia.

Bruce Robinson (B)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Cancer Genetics, Kolling Institute of Medical Research, Sydney, Australia.

Anthony J Gill (AJ)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia.
Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Alexander Guminski (A)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Thomas Eade (T)

Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

Matti L Gild (ML)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Cancer Genetics, Kolling Institute of Medical Research, Sydney, Australia.

Classifications MeSH